Dystrophic Epidermolysis Bullosa Treatment Market Size in the 7MM is Projected to Grow at a CAGR of 7% by 2036, estimates DelveInsight

DelveInsight's "Dystrophic Epidermolysis Bullosa Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology as well as Dystrophic Epidermolysis Bullosa market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Dystrophic Epidermolysis Bullosa Treatment Market Report @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Dystrophic Epidermolysis Bullosa Market Report
• The total prevalent cases of epidermolysis bullosa in the 7MM were ~47,500 cases in 2025, which is expected to increase during the forecast period (2026-2036).
• The highest number of prevalent cases was observed in the United States. On the other hand, among EU4 and the UK countries, the highest number of epidermolysis bullosa cases was observed in Germany in 2025.
• In 2025, the total diagnosed prevalent cases of dystrophic epidermolysis bullosa in 7MM were 14,300, which are expected to increase by 2036.
• Epidermolysis bullosa simplex is the most common form of epidermolysis bullosa, accounting for approximately 61%, 5% and 34% cases of EBS, JEB, and DEB in the 7MM in 2025.
• The leading Dystrophic Epidermolysis Bullosa Companies include Krystal Biotech, Chiesi Farmaceutici, Japan Tissue Engineering, Abeona Therapeutics, Castle Creek Biosciences, and others.
• Promising Dystrophic Epidermolysis Bullosa Therapies include VYJUVEK (beremagene geperpavec), FILSUVEZ (oleogel-S10), JACE (human epidermal cell sheet), ZEVASKYN, D-Fi (dabocemagene autoficel), and others.

Get a Free sample for the Dystrophic Epidermolysis Bullosa Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Overview
DEB is a rare, inherited skin disorder characterized by extreme skin fragility, leading to recurrent blistering, erosions, and chronic wounds following minor mechanical trauma. The condition is caused by mutations in the COL7A1 gene, which encodes type VII collagen, a critical component responsible for anchoring the epidermis to the dermis. DEB is broadly classified into dominant and recessive forms, with recessive DEB generally presenting with more severe clinical manifestations, including extensive blistering, scarring, deformities, and increased risk of aggressive squamous cell carcinoma. The disease significantly impacts patients' quality of life, often requiring lifelong wound care, pain management, and multidisciplinary clinical support.

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Epidermolysis Bullosa
• Total Diagnosed Prevalent Cases of Epidermolysis Bullosa
• Total Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa
• Gender-specific Cases of Dystrophic Epidermolysis Bullosa
• Age-specific Cases of Dystrophic Epidermolysis Bullosa

Download the report to understand which factors are driving Dystrophic Epidermolysis Bullosa epidemiology trends @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Approved Therapies
• VYJUVEK (beremagene geperpavec): Krystal Biotech
Beremagene geperpavec (B-VEC) is a non-invasive, topical, redosable gene therapy designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds. In September 2025, Krystal Biotech announced that the US FDA approved a label update for VYJUVEK that expands the VYJUVEK eligible patient population to include DEB patients from birth and provides patients full flexibility with respect to VYJUVEK application and managing wound dressings. In July 2025, Krystal Biotech announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) granted marketing authorization to VYJUVEK for the treatment of wounds in patients with DEB, starting from birth. VYJUVEK is the first genetic medicine approved in Japan for the treatment of DEB. The Japanese approval allows for dosing at home or in a healthcare setting, with the option for administration by patients or their family members.

• FILSUVEZ (oleogel-S10): Chiesi Farmaceutici
FILSUVEZ is a herbal medicinal product that contains birch triterpenes from birch bark. This sterile gel is being developed to speed up the healing of skin wounds in adults and children with severe subtypes of epidermolysis bullosa; these subtypes are DEB and JEB. FILSUVEZ joined the Chiesi portfolio as part of the agreement reached during the acquisition of Amryt Pharma in January of this year.

Dystrophic Epidermolysis Bullosa Pipeline Analysis
• D-Fi (dabocemagene autoficel): Castle Creek Biosciences
Using its proprietary ex vivo platform, Lenti-VEX, the company is developing and evaluating D-Fi, also known as FCX-007 (dabocemagene autoficel), an autologous gene therapy candidate to treat DEB, a progressive, devastatingly painful and debilitating, rare genetic skin disorder.

• ABCB5+ mesenchymal stem cells (ABCB5+ MSCs): RHEACELL
ABCB5+ mesenchymal stem cells (ABCB5+ MSCs) may represent a new, promising therapeutic approach to epidermolysis bullosa. ABCB5+ MSCs are infused into the bloodstreams and can migrate to the wounds, decreasing inflammation and promoting wound healing. ABCB5+ MSCs target all wounds (internal and external) and release and deposit collagen VII.

Dystrophic Epidermolysis Bullosa Companies
Krystal Biotech, Chiesi Farmaceutici, Japan Tissue Engineering, Abeona Therapeutics, Castle Creek Biosciences, and others.

Discover more about therapies set to grab Major Dystrophic Epidermolysis Bullosa market share @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Market Outlook
Significant advances in understanding the pathophysiology of epidermolysis bullosa have driven the development of repurposed drugs and novel targeted therapies, particularly disease-modifying approaches aimed at restoring defective proteins. However, no curative treatments exist for most epidermolysis bullosa subtypes, and current management remains largely supportive, focusing on wound care, pain control, and prevention of complications. Wound care is the cornerstone, but it is time-intensive, costly, and places a substantial burden on patients and caregivers, especially in severe forms such as recessive dystrophic epidermolysis bullosa (RDEB).

Dystrophic Epidermolysis Bullosa Pipeline Landscape
Dystrophic Epidermolysis Bullosa emerging therapeutic strategies include gene therapy, cell-based therapies, and protein replacement approaches. While early studies (e.g., fibroblast injections and bone marrow transplantation) have shown partial benefits, challenges related to safety, tolerability, and durability remain. Japan has led in cell therapy approvals with JACE, while Europe approved FILSUVEZ for wound treatment. A breakthrough occurred in 2023 with the US approval of VYJUVEK, the first topical gene therapy for DEB, which promotes wound healing and reduces blister formation.

To know more about Dystrophic Epidermolysis Bullosa companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dystrophic Epidermolysis Bullosa Market Report
• Coverage- 7MM
• Study Period: 2022-2036
• Forecast Period- 2026-2036
• Dystrophic Epidermolysis Bullosa Companies- Krystal Biotech, Chiesi Farmaceutici, Japan Tissue Engineering, Abeona Therapeutics, Castle Creek Biosciences, and others.
• Dystrophic Epidermolysis Bullosa Therapies- VYJUVEK (beremagene geperpavec), FILSUVEZ (oleogel-S10), JACE (human epidermal cell sheet), ZEVASKYN, D-Fi (dabocemagene autoficel), and others.
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment- Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers
• Dystrophic Epidermolysis Bullosa Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dystrophic Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Dystrophic Epidermolysis Bullosa Market Access and Reimbursement

Table of Contents
1. Dystrophic Epidermolysis Bullosa Market Report Introduction
2. Executive Summary for Dystrophic Epidermolysis Bullosa
3. SWOT analysis of Dystrophic Epidermolysis Bullosa
4. Dystrophic Epidermolysis Bullosa Patient Share (%) Overview at a Glance
5. Dystrophic Epidermolysis Bullosa Market Overview at a Glance
6. Dystrophic Epidermolysis Bullosa Disease Background and Overview
7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Dystrophic Epidermolysis Bullosa
9. Dystrophic Epidermolysis Bullosa Current Treatment and Medical Practices
10. Dystrophic Epidermolysis Bullosa Unmet Needs
11. Dystrophic Epidermolysis Bullosa Emerging Therapies
12. Dystrophic Epidermolysis Bullosa Market Outlook
13. Country-Wise Dystrophic Epidermolysis Bullosa Market Analysis
14. Dystrophic Epidermolysis Bullosa Market Access and Reimbursement of Therapies
15. Dystrophic Epidermolysis Bullosa Market Drivers
16. Dystrophic Epidermolysis Bullosa Market Barriers
17. Dystrophic Epidermolysis Bullosa Appendix
18. Dystrophic Epidermolysis Bullosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.